Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2.

Next Previous
Search
Trial Profile

Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Angiotensin receptor antagonists
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms SMART-2

Most Recent Events

  • 27 Feb 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
  • 03 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
  • 01 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 31 Oct 2011.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top